NASDAQ · Biotechnology

TTRX (TTRX) Stock

$8.02 +3.02% NASDAQ: TTRX Healthcare

Valuation

MetricValue
Price$8.02
Market Cap$238.75M
P/E Ratio-27.91
P/B Ratio31.32
P/S Ratio0.00
EPS (TTM)$-0.23
52-Week High$26.50
52-Week Low$2.57
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-129.17%
ROA-25.00%
ROCE-120.00%
Gross Margin0.00%
Operating Margin0.00%
Net Margin0.00%
Debt/Equity0.98
Current Ratio0.83

Annual Financials (USD)

Metric202320242025
Revenue$0$0$0
Operating Profit$-2.0M$-2.0M$-6.0M
Net Profit$-2.0M$-2.0M$-3.0M
EPS$-0.17$-0.13$-0.23
Op Margin———

Balance Sheet (USD)

Metric202320242025
Total Assets$2.0M$2.0M$12.0M
Total Liabilities$2.0M$2.0M$7.0M
Cash$1.0M$1.0M$5.0M
Borrowings$0$0$0

Latest News

Turn Therapeutics Refines GX-03 Eczema Trial After Interim Data, Eyes 2026 Readout MarketBeat · Jul 11, 2026 Turn Therapeutics’ stock jumps on AD data and trial expansion Clinical Trials Arena · Jul 8, 2026 Turn Therapeutics Completes Interim Phase 2 Review; Expands GX-03 Study in Atopic Dermatitis MT Newswires · Jul 7, 2026 Turn Therapeutics Announces Final Stage 2 Design and Data-Driven Expansion of GX-03 Phase 2 Program in Atopic Dermatitis Business Wire · Jul 7, 2026 Turn Therapeutics to Host Webcast Presenting Comprehensive Interim Analysis and Optimized Stage 2 Design for GX-03 in Atopic Dermatitis Business Wire · Jul 6, 2026

Cash Flow (USD)

Metric202320242025
Operating Cash Flow$-1.0M$-1.0M$-3.0M
Investing Cash Flow$0$0$0
Financing Cash Flow$0$0$0
Net Cash Flow$-1.0M$0$4.0M
Free Cash Flow$-1.0M$-1.0M$-3.0M

Valuation & Return Ratios

MetricValue
PEG Ratio—
EV / EBITDA-22.89
FCF Yield-2.04%
Quick Ratio2.23
Interest Coverage—
Return 1Y—
Return 3Y—
Return 5Y—

Ownership

Insiders Held54.12%
Institutions Held2.62%
Institutions Float Held5.71%
Institutional HolderSharesReport Date
SteelPeak Wealth, LLC249,4562026-06-30
Ddfg, Inc 70,5342026-03-31
Millennium Management Llc69,7572026-03-31
Wellington Shields & Co., LLC65,7322026-03-31
Vanguard Capital Management LLC49,4502026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
AGENAgenus Inc. $6.06 +1.34% 3.46 $252.35M 0.00%
ANIX $3.48 -1.14% -8.00 $118.40M 0.00%
CGTX $0.89 +0.21% -3.94 $79.79M 0.00%
GLSI $14.36 +0.84% -21.98 $210.78M 0.00%
HURA $2.09 -2.34% -3.75 $133.10M 0.00%

About TTRX

TTRX is led by CEO Bradley E. Burnam, employs 2 people, headquartered in US, publicly traded since 2025.

TTRX stock trades at $8.02 with a market capitalization of $238.75M. The stock is valued at a price-to-earnings (P/E) ratio of -27.91, price-to-book of 31.32, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $2.57 and $26.50, and currently trades 69.7% below its 52-week high.

On profitability, TTRX generates a return on equity (ROE) of -129.17%, return on capital employed of -120.00%, an operating margin of 0.00%, a net profit margin of 0.00%.

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides